Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
ARRY-334543, EGFR/ErbB2 inhibitor · 5 trials · 2 indications
| Arm | Type | Description |
|---|---|---|
| ARRY-334543 + gemcitabine | EXPERIMENTAL | - |
| ARRY-334543 + docetaxel + prophylactic growth factors | EXPERIMENTAL | - |
| ARRY-334543 + capecitabine | EXPERIMENTAL | - |
| ARRY-334543 | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| ARRY-334543, EGFR/ErbB2 inhibitor; oral | DRUG | multiple dose, escalating |
| Gemcitabine, nucleoside analogue; intravenous | DRUG | multiple dose, single schedule |
| Docetaxel, mitotic inhibitor; intravenous | DRUG | multiple dose, single schedule |
| Prophylactic growth factors; subcutaneous | DRUG | standard of care |
| Capecitabine, 5-fluorouracil prodrug; oral | DRUG | multiple dose, single schedule |
Key Inclusion Criteria (Part 1): * Histologically or cytologically confirmed diagnosis of a solid tumor suitable for treatment with gemcitabine. * No more than 3 prior anticancer regimens for advanced disease. * Measurable or evaluable, nonmeasurable disease. * Eastern Cooperative Oncology Group (E...
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| GE Healthcare Technologies Inc. | GEHC | 1 | PHASE1 | GEH200520/ GEH200521- Part A |
| Zimmer Biomet Holdings, Inc. | ZBH | 1 | - | Undisclosed |
| Ascentage Pharma Group International Unsponsored ADR | AAPG | 1 | PHASE1 | Olverembatinib |
ARRY-334543 is an investigational small molecule being studied for the treatment of advanced cancer. It is a targeted therapy that inhibits EGFR and ErbB2, two proteins involved in cancer cell growth. The drug is currently in Phase 1 clinical development and has not been approved by the FDA.
ARRY-334543 targets EGFR and ErbB2, which are receptor tyrosine kinases involved in cell signaling and tumor growth. By inhibiting these targets, the drug aims to block pathways that drive cancer cell proliferation. This mechanism is being evaluated in patients with advanced cancer.
Pfizer, Inc. (NYSE: PFE) is developing ARRY-334543. The company has sponsored multiple Phase 1 clinical trials of the drug in patients with advanced cancer. As of now, the drug remains in early-stage clinical development.
ARRY-334543 is in Phase 1 clinical development. It is an investigational drug, meaning it has not been approved by regulatory authorities. Five Phase 1 trials have been completed, all of which were uncontrolled and non-randomized, with a total enrollment of 203 patients.
ARRY-334543 has been studied in five completed Phase 1 trials. These include NCT00278902 and NCT00637702, which evaluated the drug alone in advanced cancer, and NCT00710736 and NCT00833326, which tested it in combination with capecitabine and docetaxel, respectively. All trials enrolled adults with advanced cancer.
Yes, ARRY-334543 is an EGFR/ErbB2 inhibitor. This means it is designed to block the activity of EGFR and ErbB2, two proteins that can promote cancer growth. The drug is being investigated as a potential treatment for advanced cancer, though it remains in early clinical testing.